– USA, NY – Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company’s Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Therapeutics, a biotechnology company focused on the development of therapies for a broad range of rare and orphan diseases.
“As we continue to progress toward key milestones, including the upcoming July 19th PDUFA date for Oral RELISTOR® and pivotal Phase 2b topline results for AZEDRATM, we welcome Bradley to our Board of Directors and look forward to leveraging his commercial and operational expertise,” said Mark Baker, Chief Executive Officer of Progenics. “His leadership will be invaluable not only as we advance AZEDRA, our ultra-orphan radiotherapy drug candidate, toward potential FDA approval, but also work to advance and commercialize our prostate cancer portfolio.”
“The Progenics team has assembled a diverse portfolio of assets that I believe hold significant value for patients and compelling opportunity for shareholders,” said Mr. Campbell. “I am eager to begin working with my fellow directors and the senior leadership team as the Company grows and transitions from an R&D-focused organization to a fully-integrated commercial-stage oncology company.”
Prior to joining Amicus Therapeutics in 2006, Mr. Campbell held senior positions at Genzyme from 2002 to 2004 and, before that, Bristol-Myers Squibb from 1999 to 2000. Mr. Campbell began his career at Marakon, a global management consulting firm. He received a Bachelor of Arts degree in public policy studies from Duke University and an MBA from Harvard Business School.
About Progenics
Progenics Pharmaceuticals, Inc. is developing innovative medicines and other products for targeting and treating cancer, with a pipeline that includes several product candidates in later-stage clinical development. These products in development include therapeutic agents designed to precisely target cancer, and PSMA-targeted imaging agents for prostate cancer intended to enable clinicians and patients to accurately visualize and manage their disease. Progenics recently entered into an agreement with a subsidiary of Bayer AG granting Bayer exclusive worldwide rights to develop and commercialize products using our PSMA antibody technology in combination with alpha-emitting radionuclides. In addition, in late 2015 Progenics acquired EXINI Diagnostics AB, a leader in the development of advanced artificial intelligence-based imaging analysis tools and solutions for medical decision support. The acquisition of EXINI complements Progenics’ strategy to support its imaging and therapeutic agents with sophisticated analytical tools and other technologies to help physicians and patients visualize, understand, target and treat cancer. Progenics’ first commercial product, RELISTOR for opioid-induced constipation, is partnered with and marketed by Valeant Pharmaceuticals International, Inc.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
